1nvestor;
Nothing stops Abbot from buying BOCX. Abbot bought Urovysion, even though (according to Half Full) their cancer detection technology is much less impressive than BOCX's. Maybe Abbot knows something we don't?
Another recent event (or non-event) that worried me was BOCX's presentation at the American Association for Clinical Chemistry (AACC) Annual Meeting. According to BOCX's press release, this is the largest clinical lab meeting in North America. Yet, after the presentation, there was no pop in the share price at all. Perhaps the attendees at the meeting, who presumably are experts in the field, weren't impressed by the results, or didn't believe them? The best spin that could be put on this is that hardly anyone attended BOCX's presentation.
Of course, this all just amounts to reading tea leaves. But until Moro et al put out some concrete info, that's all we can do.
A1
